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Summary The value of chemotherapy in advanced non-small cell lung cancer (NSCLC) remains contentious.
Because of this two separate but very similar trials were set up in Australia and Southampton (UK). Two
hundred and one patients with stage IIIb or IV NSCLC were randomly assigned to cisplatin 120 mg m 2 on
days 1 and 29 and vindesine 3 mg m-2 weekly x 6 or to no chemotherapy. Both groups were eligible to receive
radiotherapy or other palliative treatment as required. Of 188 evaluable patients, 97 received chemotherapy
and 91 were in the control arm. Response was assessed between days 42 and 49. Responders continued
chemotherapy at the same doses though cisplatin being given 6 weekly x 4 and the vindesine 2 weekly x 12.
The overall response rate to chemotherapy was 28%; there were no significant differences according to major
prognostic criteria. Although the overall survival of the chemotherapy group (median 27 weeks) was longer
than that of the no chemotherapy group (median 17 weeks) this was not statistically significant (log rank
P = 0.33). For patients without dissemination (IlIb), median survival was 45 weeks in the chemotherapy arm
and 26 weeks in the non-chemotherapy (log rank P = 0.075). Toxicity was universal and frequently severe: of
17 patients discontinuing chemotherapy after one cycle, 13 did so because of unacceptable toxicity. This
chemotherapy cannot be recommended as routine treatment. Further phase III studies of chemotherapy in
advanced NSCLC should continue to use a no chemotherapy control and should also attempt to measure
quality of life, an issue not addressed effectively in this or other recent trials.
Metastatic or locally advanced non-small cell lung cancer has
been notoriously difficult to treat. Although radiotherapy is
of palliative value, individual cytotoxic agents have only
produced low objective response rates and those responses
reported have been of short duration (Hoffman et al., 1983).
During the past 20 years combination chemotherapy has
been extensively tested in randomised multicentre and single
institution studies though almost always without a no treat-
ment control (Simes, 1985; Dhingra et al., 1985). In general,
studies comparing different combinations have yielded
relatively low response rates and very similar patterns of
survival regardless of therapy. During the past decade the
introduction of more intensive chemotherapy, often based on
cisplatin, has resulted in an apparent small improvement in
survival and a modest increase in response to therapy, but at
the expense of greater toxicity (Dhingra, 1985; Klastersky &
Sculier, 1985). High dose cisplatin regimes were introduced
following the randomised study in which Gralla et al. (1981)
demonstrated that a dose of 120 mg m-2 every 4 weeks was
superior to a dose of 60 mgm-2 in the same schedule. The
use of this drug in high dose inevitably causes marked tox-
icity in this elderly group of patients who frequently have
other concurrent medical problems.
When this study was instituted only one small randomised
study has shown a survival advantage for combination
chemotherapy (MACC) over no chemotherapy (Cormier et
al., 1982). Because of the need to define clearly the
therapeutic potential of platinum based chemotherapy,
separate but almost identical randomised trials were begun in
Australia and in Southampton, UK. Both compare Gralla's
cisplatin and vindesine regime (Gralla et al., 1981), which
was considered to be optimal therapy at the time the study
was initiated, with a policy of giving no chemotherapy at any
time during the patients' disease course.
Patients and methods
All patients had histologically proven non-small cell lung
cancer of squamous, adenocarcinoma or large cell type.
Patients had extensive disease (metastatic or bulky unresect-
able local disease) according to the American Joint Commit-
tee (AJC) staging system of 1979 (stage III, Mo or M,)
(Mountain et al., 1979). According to the new AJC system
these patients would now be classified as stage IlIb or stage
IV disease (American Joint Committee on Cancer, 1988). All
patients were 75 years or less, were ECOG performance
status 0-3 and had measurable or evaluable disease. None
had received prior chemotherapy. Prior irradiation (more
than 4 weeks previously) was allowed in the Australian study
if patients showed clear disease progression following
radiotherapy but not in the Southampton study.
Eligible patients had a normal base-line blood count
(WBC>4 x 109 1-1, platelets > 100 x 109 1'), renal function
(serum creatinine < 130 ;Lmol ') and liver function (serum
bilirubin <20jtmol 1').
Patients with brain metastases, ECOG performance status
4 or concomitant illness likely to prejudice therapy were
excluded. Informed consent was obtained from all patients
according to the requirements of local ethical committees.
Study design
The two protocols in Australia and Southampton only
differed in two respects: the acceptance of prior radiotherapy
in the Australian study already mentioned and the ran-
domisation procedure. The Australian study used the pre-
consent randomisation technique of Zelan (1979), while in
Southampton randomisation was only undertaken after
patient consent. The two trial schemes are shown in Table I.
Patients were stratified by the parameters outlined in the
table. Pathology review was conducted independently in Aus-
tralia and Southampton, data collection being undertaken by
data managers in each centre with statistical analysis being
performed in Sydney.
Treatment
Patients randomised to cytotoxic treatment received two
cycles of chemotherapy in the doses outlined in Table I.
Doses of chemotherapy were adjusted on the basis of blood
count on the day of treatment and on creatinine clearance.
Patients in this treatment group were eligible to receive pal-
liative radiotherapy for superior vena caval obstruction,
haemoptysis, bronchial obstruction, painful bone metastases
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Refused randomisation
off study
Cisplatina
Vindesine
No chemotherapy
Southampton study
Stratification
Histology Randomisation Cisplatina
Squamous Vindesine
Adenocarcinoma
Large cell No chemotherapy
Performance status
0,1 vs 2,3
aCisplatin 120 mg m-2 i.v. day 1, and 29, then 6 weekly x 4. Vindesine
3 mg m-2 weekly x 6, then every 2 weeks x 12. Responders received a
maximum of 6 cycles.
and brain metastases at any time. Patients randomised to the
other arm were able to receive similar irradiation as and
when required. At no time were they eligible to be treated
with cytotoxic therapy.
Patients in both groups were also treated palliatively with
analgesics, antibiotics, corticosteroids, diphosphonates and
other drugs as required. Anti-emetics were used routinely and
consisted of dexamethasone, domperidone and lorazepam.
Evaluation
All patients were evaluated on trial entry by clinical history,
physical examination, full blood count, serum biochemistry
and chest X-rays. Other imaging techniques were only used
when warranted by the clinical situation. Chemotherapy
patients were re-evaluated after two cycles of cisplatin-
vindesine between days 42 and 49. For patients with
measurable or evaluable disease standard response criteria
were used (Miller et al., 1981). Chemotherapy toxicity was
assessed after each treatment cycle and graded according to
the WHO toxicity criteria (World Health Organization,
1979).
Survival time was measured from the date of randomisa-
tion until death and progression-free survival from ran-
domisation to the date that progression was documented.
Statistical analysis of survival was undertaken using the log
rank method (Peto et al., 1977).
Results
Patient characteristics
Between January 1984 and January 1987, 201 patients were
accrued into the study. Thirteen patients in the Australian
part of the study were unwilling to be treated with the arm to
which they had been randomised before obtaining consent
(eight chemotherapy, five no chemotherapy). Thus, 188
patients were eligible for study (159 in five Australian centres
and 29 in Southampton). Of these, 97 were randomised to
receive chemotherapy with cisplatin and vindesine and 91 to
receive no chemotherapy. Four patients randomised to
receive cisplatin and vindesine were treated with alternative
drug therapy, a decision made by the patient's physician:
none responded, but all have been included in this analysis.
The pre-treatment characteristics of the two arms of the
study are similar (Table II), although there is an excess of
patients with limited disease in the no chemotherapy group
Table II Pre-treatment characteristics ofeligible patients
Cisplatin, No All
Characteristic vindesine (%) chemotherapy (%) patients
Median age (years)
Sex
Male
Female
Adenocarcinoma
Squamous cell
Large cell
ECOG PS
0-1
2-3
Limited diseasea
Extensive disease
Nodal only
Bone
Liver
Skin
Other
Multiple
61 61
73 (78)
20 (22)
35 (37)
36 (39)
22 (24)
68 (73)
25 (27)
25 (27)
20 (22)
11(12)
2 (2)
1 (1)
8 (9)
26 (28)
61
81 (85)
14 (15)
33 (35)
36 (38)
26 (27)
69 (73)
26 (27)
39 (41)
21 (22)
10 (11)
5 (5)
2 (2)
8 (9)
10 (11)
154
34
68
72
42
137
51
64
41
21
7
3
16
36
aDisease confined to the ipsilateral chest and mediastinum.
and an excess of patients with multiple metastatic sites in the
chemotherapy group. These differences did not reach statis-
tical significance. The median age of patients was 61 years,
82% were men and the majority (73%) had an ECOG per-
formance status score of 0 or 1. The age and performance
status of patients and the proportion with limited disease in
this study reflect a selected population with more favourable
prognostic criteria than usually seen outside a trial setting.
Response and survival
Response was evaluated between days 42 and 49, after the
patients had completed two cycles of chemotherapy. All
patients were considered evaluable regardless of the amount
of chemotherapy that they had received. Table III shows the
objective response rates for patients in the cisplatin/vindesine
arm of the trial. The overall response rate was 28%. There
were no significant differences according to histological type,
performance status (0, I vs 2, 3) or extent of disease.
Median duration of response for patients receiving
chemotherapy was 40 weeks. Performance status, disease
extent and histological type failed significantly to affect
progression-free survival.
Overall survival for all patients is shown in Figure 1.
Although the median survival for the chemotherapy group
(27 weeks) exceeds that of the no chemotherapy arm (17
weeks), the survival experience of the two groups was not
significantly different (log rank P = 0.33). Survival of patients
in the limited disease group was longer than for those with
extensive disease. The median survival of patients with
Table III Objective response rate to cisplatin vindesine
No. No. CR No. PR Overall
Characteristics patients (%) (%) response (%)
All patients 97 6 (6) 21 (22) 27 (28)
ECOG PS
0 23 1 (4) 1 (4) 9 (39)
1 37 5 (14) 6 (16) 11 (30)
2 18 0 3 3 (17)
3 4 0 2 2(50)
Unknown 15 0 2 2 (13)
Adenocarcinoma 37 2 (5) 8 (22) 10 (27)
Large cell 24 2 (8) 2 (8) 4 (17)
Squamous cell 34 2 (6) 11 (32) 13 (38)
Bronchiolar 2 0 0 0
alveolar cell
Limited disease 28 2 (7) 7 (25) 9 (32)
Extensive disease 69 4 (6) 14 (20) 18 (26)
No. sites of
met. dis.
Single 43 4 (9) 16 (37) 20 (47)
Multiple 26 3 (12) 4 (15) 7 (27)
Table I Outline of trial design
Australian study
Stratification
Histology:
Squamous
Adenocarcinoma
Large cell
Performance status
0,1 vs 2,3
Prior radiotherapy
yes, no
Pre-consent
randomisation610 R.L. WOODS et al.
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Figure 1 Overall survival of all evaluable patients according to
randomised group (cisplatin/vindesine 97 patients, no
chemotherapy control 91 patients). There is no significant
difference in survival. Log rank P = 0.33; chemotherapy; ---
no chemotherapy.
limited disease treated with chemotherapy (45 weeks) was
appreciably longer than for non-chemotherapy patients (26
weeks), but the overall survival experience of the two groups
was not significantly different (Figure 2, log rank P = 0.075).
Toxicity and quality oflife
Toxicity, recorded using the WHO grading scale, was severe.
All patients reported subjective side effects which were life
threatening or serious in about one half (Table IV). Seven-
teen patients discontinued chemotherapy after one cycle: 13
because of unacceptable toxicity and four because of tumour
progression. The predominant cause of early discontinuation
of therapy was emesis, despite the use of intensive antiemetic
therapy (high dose metoclopramide, lorazepam, dexa-
methasone). Although severe neutropenia was common,
thrombocytopenia was not a problem. Mucositis was only
rarely reported.
Analysis of serial performance status scores failed to show
any significant difference between the two arms of the study.
(Mean fall in performance status during chemotherapy -1,
median fall -2, range of change in performance + 2 to -4
points on performance scale. Changes in the same period in
non-chemotherapy patients were mean - 0.65, median - 1,
range + 2 to - 3.)
Discussion
Combination chemotherapy, often including cisplatin, has
been extensively used in non-small cell lung cancer during
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Figure 2 Overall survival of patients with limited disease accord-
ing to randomisation group (cisplatin/vindesine 25 patients, no
chemotherapy 39 patients). The difference approaches statistical
significance. Log rank P = 0.075; chemotherapy;
--- no
chemotherapy.
Table IV Moderate to severe toxicity ofcisplatin/vindesine
Proportion ofpatients
Side-effect experiencing toxicity (%)
Myelotoxicity WHO III or IV 38 (45%)'
Nephrotoxicity WHO II, III, IV 20 (24%)b
Emesis WHO III or IV 31 (36%)
Alopecia WHO II 29 (34%)
Neurological WHO I, II, III 29 (34%)
aFive had life-threatening infections but none died. bIn six patients
renal dysfunction was temporary.
this decade (Klastersky & Sculier, 1985; Cartei et al., 1988).
Most randomised studies have compared differing regimes of
two, three of four drugs. Disappointingly, very few of these
have shown any survival differences between the treatments
tested despite moderate sized trials (Simes, 1985). One con-
clusion from these data may be that, despite encouraging
response rates, none of these treatments is sufficiently active
to make a major improvement in survival over that of a
policy of no chemotherapy. This study reports data that
support this hypothesis. Despite an objective response rate of
28%, vindesine and cisplatin, as used in this study, failed to
improve survival significantly compared to that of patients
randomised to receive no chemotherapy. Although survival
appeared to be of longer duration in chemotherapy patients
with limited disease, this difference did not achieve statistical
significance and at best would only amount to some extra
weeks life. Such a gain must be seen in the light of severe
toxicity in a high proportion of patients.
These results are somewhat different from those reported
by Rapp et al. (1988). In their randomised three-arm trial
cisplatin, vindesine (VP) was compared with cyclophosamide,
doxorubicin, cisplatin (CAP) and with best supportive care
only. One hundred and thirty-seven patients were eligible for
analysis, under 50 in each arm. Median survivals were 32.6
weeks when treated with VP, 24.7 weeks with CAP and 17
weeks in the control arm (chemotherapy vs control, P= 0.02;
VP vs control, P = 0.01; CAP vs control, P= 0.05).
Differences between this trial and our own include: 1. In
the Canadian study, chemotherapy was only discontinued for
progressive disease, unacceptable toxicity or patient refusal.
In our study only patients with an objective response after
two cycles of therapy continued cisplatin/vindesine. 2. The
Canadian study restricted entry to patients with an ECOG
performance status of 0, 1 and 2. In our series patients with
ECOG performance status 3 were also included. 3. Patients
in the present series were also older than those in the study
reported by Rapp et al. (1988) (median age: 61 years com-
pared with 57 years).
Comparison of results does, however, show that survival in
the two no chemotherapy groups was very similar (median 16
vs 17 weeks). Cisplatin/vindesine in our study gave survival
rates very similar to the Canadian CAP arm (median 27 vs
24.7 weeks respectively), although the results were marginally
inferior to the Canadian VP arm (median 32.6 weeks). One
possible explanation for the apparent improved survival in
the VP arm of the Canadian study was that they continued
chemotherapy in patients with stable disease, whereas treat-
ment was stopped in similar patients in our own study.
However, even in the Canadian study improvement in
survival was not substantial and was bought at the expense
of marked toxicity. Severe, life-threatening or lethal toxicity
was more common in their VP arm where leucopenia of this
grade was seen in 40%, vomiting 23% and neurological
toxicity 16%. Lesser degrees of toxicity were, presumably,
more common. In our study, severe leucopenia was seen in a
similar proportion of patients although grade III and IV
emesis was more common. Unacceptable side-effects were the
commonest reason for early discontinuation of therapy,
underlining the unpleasant nature of the treatment.
A study reported by Celleriono et al. (1988) compared six
drug chemotherapy (cyclophosphamide, epirubicin, cisplatin,
alternating with methotrexate, etoposide and CCNU) with
best supportive care in 92 patients. The response rate in the
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38 evaluable chemotherapy patients was 21%; comparison of
survival with that in the supportive care arm (39 patients)
showed no significant differences (median survival: 8.5
months chemotherapy vs 5.0 months supportive care;
Mantel-Cox P = 0.56).
Other similar randomised studies have, in general, failed to
find a survival advantage for chemotherapy over no treat-
ment, although some of these have used therapy that would
now be thought to be ineffective (Laing et al., 1975; Durrant
et al., 1971). Ganz et al. (1987) used vinblastine (6mgm2
week-') and cisplatin (120mgm-2 per 4 weeks) to treat 22
patients randomised to chemotherapy; 26 patients did not
receive chemotherapy. Objective responses were seen in 18%
of chemotherapy patients, but there were no significant
differences (P = 0.32) in overall survival (median survival,
19.9 weeks chemotherapy vs 14.4 weeks no chemotherapy).
The only randomised study, other than that of Rapp et al.,
to show a survival advantage for chemotherapy over a policy
of no chemotherapy is that of Cormier et al. (1982). The
conclusions of this study are open to discussion since it was
very small (only 39 patients) and the no treatment group had
a particularly short survival (median 8.5 weeks).
Interpretation of results from all these trials must take into
account the apparently relatively small survival gain in a
setting of moderate to severe toxicity in an appreciable pro-
portion of patients. Although objective responses have been
reported in up to 30% of patients, no data have been pre-
sented to show whether these patients felt symptomatically
better or had improved quality of life. Attempts to measure
quality of life were not made in our study since no univers-
ally accepted technique was available. In the studies of Rapp
et al. (1988) and Ganz et al. (1987) attempts to measure
quality of life failed because of lack of patient compliance
and a suitable method. There are, therefore, no data upon
which the small survival benefit can be balanced against
quality of remaining life. In the cost-benefit analysis of
ECOG studies reported by Simes et al. (1985), patients spent
48% of their remaining life on chemotherapy and 18% spent
all of their remaining life on chemotherapy.
An indirect attempt to approach this problem has been
made by MacKillop et al. (1986), who asked 118 experts in
the management of lung cancer to take part in a surrogate
study. They were given three scenarios which included ran-
domised trials with chemotherapy. They were asked to
imagine themselves as the patient and to then decide whether
they would consent to enter the trial. In the three scenarios
presented that included chemotherapy, the expert doctors
said they would refuse consent to the trial in 69%, 81% and
89% of cases. Reasons for refused consent were toxicity of
the treatments (60-70%) and their lack of effectiveness
(60-74%). Although the validity of such an approach is
unproven, this study suggests that the clinicians in this series
did not feel that the potential small benefits of chemotherapy
were worth the toxicity and that it was their perception that
quality of life was not enhanced.
The study presented here is the largest randomised trial
comparing a cisplatin based combination with no
chemotherapy published to date. Its findings are in general
agreement with those of Rapp et al. (1988). Our interpreta-
tion of these data is, however, different. Although there is a
small survival benefit in the chemotherapy group of the
Canadian study and a suggestion of similar benefit in a
subgroup of our study, neither trial makes a convincing case
for the routine use of such chemotherapy in advanced non-
small cell lung cancer since this small advantage is gained at
the expense of marked toxicity. Rather, they show the need
for a real improvement in the therapy of this disease. Until
improved quality of life and survival is unequivocally demon-
strated a best supportive care group should be used as the
control for future phase III trials and such studies should
endeavour to measure quality of life as well as survival.
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